From Medscape Oncology

Coverage from the

American Society of Hematology 2021 Annual Meeting

December 11 - 14, 2021; Virtual/Online & In Person in Atlanta, Georgia

December 11 - 14, 2021 Virtual/Online & In Person in Atlanta, Georgia

ASH 2021 AGILE: 'Exciting' Survival Results for IDH1-mutated AML Older patients not eligible for intensive chemotherapy had higher complete remission rates and longer overall survival when ivosidenib was added onto azacitidine in the AGILE phase 3 trial.
Medscape Medical News, December 13, 2021
ASH 2021 'Outstanding Data': Mosunetuzumab in R/R Follicular Lymphoma The investigational monoclonal antibody showed impressive activity in patients with follicular lymphoma that had relapsed or was refractory to a median of 3 prior lines of therapy.
Medscape Medical News, December 11, 2021
ASH 2021 'Remarkable' Results With CAR T Cells Could Make Chemo Obsolete Chemotherapy, the decades-old approach to second-line therapy for relapsed/refractory large B cell lymphomas, may soon be obsolete, investigators say.
Medscape Medical News, December 11, 2021

Conference News

ASH 2021 New Approaches to Hemophilia Treatment: 'Our Cup Runneth Over'
Medscape Medical News, December 22, 2021
ASH 2021 Novel Agents for Adult ALL: Is it Curtains for Chemo?
Medscape Medical News, December 21, 2021
ASH 2021 Fitusiran: Great 'Leap Forward' in Hemophilia Treatment
Medscape Medical News, December 21, 2021
ASH 2021 CAR T Cell Disappoints as Second-line for NHL in Phase 3 Trial
Medscape Medical News, December 17, 2021
ASH 2021 TKI/BiTE Combo Extends Survival of Older Patients With Ph+ALL
Medscape Medical News, December 14, 2021
ASH 2021 AGILE: 'Exciting' Survival Results for IDH1-mutated AML
Medscape Medical News, December 13, 2021
ASH 2021 Talk Early to Patients With High-Risk AML About End of Life
Medscape Medical News, December 12, 2021

ASH 2021 Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS
Medscape Medical News, December 12, 2021
ASH 2021 Myeloid Patients Respond Robustly to Moderna COVID Vaccine
Medscape Medical News, December 12, 2021
ASH 2021 Isatuximab Added to RVd Boosts Response in New Myeloma
Medscape Medical News, December 12, 2021
ASH 2021 Beta-Thalassemia Gene Therapy Achieves Transfusion Independence
Medscape Medical News, December 12, 2021
ASH 2021 'Outstanding Data': Mosunetuzumab in R/R Follicular Lymphoma
Medscape Medical News, December 11, 2021
ASH 2021 'Remarkable' Results With CAR T Cells Could Make Chemo Obsolete
Medscape Medical News, December 11, 2021
ASH 2021 ASH Meeting: Diversity, Inclusion, Immunotherapy, and COVID-19
Medscape Medical News, December 1, 2021

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Highlights in Acute Lymphoblastic Leukemia From ASH 2021
Mark R. Litzow, MD
Top Data in Mantle Cell Lymphoma From ASH 2021
Peter Martin, MD
Key Reports in Lymphoma CAR T Therapies From ASH 2021
David Miklos, MD
Advances in Multiple Myeloma From ASH 2021
Amrita Krishnan, MD
Top Findings in Myelodysplastic Syndromes From ASH 2021
Uwe Platzbecker, MD
CLL Updates From ASH 2021
Jennifer Brown, MD, PhD

Popular News from ASH 2020

'Practice Changing': Ruxolitinib as Second-Line in Chronic GVHD A significant advantage was observed for ruxolitinib, as compared with standard therapy, for the treatment of chronic graft-versus-host disease (GVHD).
Medscape Medical News, Dec 07, 2020
No Benefit From Tranexamic Acid Prophylaxis in Blood Cancers Tranexamic acid prophylaxis did not reduce bleeding among patients with hematologic malignancies and severe thrombocytopenia and may do more harm than good.
Medscape Medical News, Dec 07, 2020
Early Responders Could Halt Advanced CLL Combo Therapy Ibrutinib plus venetoclax could be stopped after 14 months in patients with relapsed/refractory chronic lymphocytic leukaemia if they achieve an early drop in residual disease, say UK researchers.
Medscape Medical News, Dec 08, 2020

Previous Coverage